Strengthening the clinical supply chain for individualized therapies

Published: 5 August 2021
Interview
James Andrew Case
James Andrew Case
Head of Clinical Supply Chain – Individualized Therapies, Genentech

Andy Case is a Supply Chain and Supply Chain Technology professional in the Bio-Pharmaceutical space. He is a subject matter expert in Chain of Identity and Chain of Custody for individualized cell therapies and the orchestration platforms designed to control COI/COC and supply chain activities for these therapies. Andy worked for four years at Novartis as Sr. Director of Supply Chain Technology and as a member of the team that launched Kymriah as the System Owner for CellChain the orchestration platform established by Novartis for its Cell and Gene therapies business. He is currently Head of Clinic Supply Chain, Individualized Therapies at Genentech/Roche where he is establishing supply chain capabilities for a portfolio of individualized therapies in clinical development. Andy has a BS in Civil Engineering from Texas A&M University and an MBA from IMD in Lausanne, Switzerland.

Read now